ERBB2 and breast cancer: In the chemotherapy cycle, retrospective studies found that for lymph node-negative and HER2- BC patients, four cycles of docetaxel and cyclophosphamide adjuvant chemotherapy are the most beneficial in the long-term survival of patients [18].